IMRX News and Press, Immuneering Corporation From 03/15/24

2024-03-15 10:00:13 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

2024-03-14 17:02:13 ET Gainers: Immuneering Corporation ( IMRX ) +133% . Geron Corporation ( GERN ) +81% . Cardlytics ( CDLX ) +37% . Brilliant Earth Group ( BRLT ) +8% . Acacia Research Corporation ( ACTG ) +7% . Losers: ...

A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 51.9% to $0.1549 on volume of 312,863,578 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.4% to $3.51 on volume of 229,852,079 shares SoundHound AI Inc. (SOUN) fell 3.2% to $8.37 on volu...

A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...

2024-03-14 08:21:12 ET More on Immuneering Seeking Alpha’s Quant Rating on Immuneering Historical earnings data for Immuneering Financial information for Immuneering Read the full article on Seeking Alpha For further details see: Immuneerin...

- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity - - Tar...

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., for...

2024-03-11 10:10:00 ET March 11, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech and Transportation sectors. The newest biotech companies focus on cancer treatments ...

- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase 1/2a clinical trial will evaluate IMM-1-104 as monotherapy in PDAC, non-small cell lung cance...

2024-03-06 09:10:00 ET March 6, 2024 Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech Inc. ( NASDAQ: ONCY ) (TSX: ONC ), a clinical-stage i...